0000950170-24-003076.txt : 20240108 0000950170-24-003076.hdr.sgml : 20240108 20240108180126 ACCESSION NUMBER: 0000950170-24-003076 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240105 FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moore Paul Andrew CENTRAL INDEX KEY: 0001938192 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41535 FILM NUMBER: 24521288 MAIL ADDRESS: STREET 1: 114 EAST 4TH AVENUE, SUITE 800 CITY: VANCOUVER STATE: A1 ZIP: V5T 1G4 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zymeworks Inc. CENTRAL INDEX KEY: 0001937653 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 108 PATRIOT DRIVE, SUITE A CITY: MIDDLETOWN STATE: DE ZIP: 19709 BUSINESS PHONE: 302-274-8744 MAIL ADDRESS: STREET 1: 108 PATRIOT DRIVE, SUITE A CITY: MIDDLETOWN STATE: DE ZIP: 19709 FORMER COMPANY: FORMER CONFORMED NAME: Zymeworks Delaware Inc. DATE OF NAME CHANGE: 20220712 4 1 ownership.xml 4 X0508 4 2024-01-05 0001937653 Zymeworks Inc. ZYME 0001938192 Moore Paul Andrew C/O ZYMEWORKS INC. 108 PATRIOT DRIVE, SUITE A MIDDLETOWN DE 19709 false true false false Chief Scientific Officer false Common Stock 2024-01-05 4 M false 17166 0.00 A 17166 D Common Stock 2024-01-05 4 S false 7460 10.6522 D 9706 D Common Stock 2024-01-08 4 S false 2339 11.2156 D 7367 D Restricted Stock Unit 2024-01-05 4 M false 17166 0.00 D Common Stock 17166 34334 D Stock Option (Right to Buy) 10.56 2024-01-05 4 A false 90000 0.00 A 2034-01-04 Common Stock 90000 90000 D Restricted Stock Unit 2024-01-05 4 A false 60000 0.00 A Common Stock 60000 60000 D Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024. Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. The RSUs vest in three equal annual installments beginning on January 5, 2025. /s/ Daniel Dex, Attorney-in-Fact 2024-01-08